リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma

KAGEYAMA Susumu 50378452 0000-0001-7150-647X YOSHIDA Tetsuya 60510310 KOBAYASHI Kenichi 40727434 WADA Akinori 90750539 NAGASAWA Masayuki 30750525 KUBOTA Shigehisa 80759118 KUSABA Takuto 90847211 JO Fumiyasu NAKAGAWA Shota JOHNIN Kazuyoshi 90324590 NARITA Mitsuhiro 00263046 KAWAUCHI Akihiro 90240952 滋賀医科大学

2022.12.15

概要

Pembrolizumab has been widely used to treat advanced urothelial carcinoma that has progressed after first-line platinum-based chemotherapy. Because its clinical benefits are limited, biomarkers that can predict a good response to pembrolizumab are required. The prognostic nutritional index (PNI), calculated using the serum albumin level and peripheral lymphocyte count, has been evaluated as a predictive biomarker in cancer immunotherapy. The present study investigated the application of PNI as a predictive biomarker for pembrolizumab response in patients with advanced urothelial cancer. A retrospective study was conducted on 34 patients treated with pembrolizumab at Shiga University of Medical Science Hospital between January 2018 and July 2022. The posttreatment PNI (post-PNI) was calculated within 2 months of starting pembrolizumab. The present study investigated the association between post-PNI and objective response, overall survival (OS) and progression-free survival (PFS). The patient cohort was stratified into two categories, high and low post-PNI groups, with a cutoff value of post-PNI at 40. The higher post-PNI group demonstrated a better disease control rate than the lower post-PNI group (complete response + partial response + stable disease, 75 vs. 21%, P=0.004). Regarding median OS, the higher post-PNI group exhibited a significantly longer survival time than the lower post-PNI group (23.1 vs. 2.9 months, P<0.001). Similarly, the higher post-PNI group exhibited a significantly longer PFS than the lower post-PNI group (10.2 vs.1.9 months, P<0.001). Multivariate analysis showed that a higher post-PNI value was an independent predictor for OS (hazard ratio, 0.04; 95% confidence interval, 0.01-0.14; P<0.001) and PFS (hazard ratio, 0.12; 95% confidence interval, 0.04-0.35; P<0.001). The present study indicated that the post-PNI was a predictor of favorable clinical outcomes in patients treated with pembrolizumab for advanced urothelial carcinoma.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Patel VG, Oh WK and Galsky MD: Treatment of muscle invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70: 404 423, 2020.

2. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW and Sogani PC: Preliminary results of M VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403 407, 1985.

3. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CN, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multi center, phase III study. J Clin Oncol 18: 3068 3077, 2000.

4. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent LA, Petrylak DP, Choueiri TK, et al: Pembrolizumab as second line therapy for advanced urothelial carcinoma. N Engl J Med 376: 1015 1026, 2017.

5. Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, et al: Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: A systematic review and meta analysis. Int J Clin Oncol 27: 59 71, 2022.

6. Ni L, Huang J, Ding J, Kou J, Shao T, Li J, Gao L, Zheng W and Wu Z: Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta analysis. Front Nutr 9: 823087, 2022.

7. Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D, Zhong J and Osman I: Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer 8: e001674, 2020.

8. Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y, Owari C, Itami Y, Nakai W and Anai S: Clinical impact of sarcopenia and inflammatory/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab. Diagnostics (Basel) 10: E310, 2020.

9. Ishiyama Y, Kondo T, Nemoto Y, Kobari Y, Ishihara H, Tachibana H, Yoshida K, Hashimoto Y, Takagi T and iizuka J: Predictive impact of prognostic nutritional index on pembro lizumab for metastatic urothelial carcinoma resistant to platinum based chemotherapy. Anticancer Res 41: 1607 1614, 2021.

10. Eisenhauer EA, Rherasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228 247, 2009.

11. Onodera T, Goseki N and Kosaki G: Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85: 1001 1005, 1984 (In Japanese).

12. Kanda Y: Investigation of the freely available easy to use soft ware ‘EZR’ for medical statistics. Bone Marrow Transplant 48: 452 458, 2013.

13. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, ClimentMA, PetrylakDP, ChoueiriTK, NecchiA, et al: Randomized phase III KEYNOTE 045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow up. Ann Oncol 30: 970 976, 2019.

14. Davis AA and Patel VG: The role of PD L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibi tors. J Immunother Cancer 7: 278, 2019.

15. Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, et al: Putative biomarkers of clinical benefit with pembrolizumab in advanced urothe lial cancer: Results from the KEYNOTE 045 and KEYNOTE 052 landmark trials. Clin Cancer Res 28: 2050 2060, 2022.

16. OgiharaK, KikuchiE, ShigetaK, OkabeT, HattoriS, YamashitaR, Yoshimine S, Shirotake S, Nakazawa R, Matsumoto K, et al: The pretreatment neutrophil to lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum resistant metastatic urothelial carcinoma patients. Urol Oncol 38: 602.e1 602.e10, 2020.

17. Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, et al: Pre pembrolizumab neutrophil to lymphocyte ratio (NLR) predicts the efficacy of second line pembrolizumab treatment in urothelial cancer regardless of the pre chemo NLR. Cancer Immunol Immunother 71: 461 471, 2022.

18. Kurashina R, Ando K, Inoue M, Izumi K, Maruyama R, Mitani K, Takenobu H, Haruta M, Iizuka T, Kamijo T, et al: Platelet to lymphocyte ratio predicts the efficacy of pembroli zumab in patients with urothelial carcinoma. Anticancer Res 42: 1131 1136, 2022.

19. Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, et al: Prognostic value of pre treatment risk stratification and post treatment neutro phil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol 26: 169 177, 2021.

20. Tomioka Inagawa R, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, et al: The impact of Neutrophil to Lymphocyte ratio after two courses of pembrolizumab for oncological outcomes in patients with metastatic urothelial carcinoma. Biomedicines 10: 1609, 2022.

21. Fujiwara M, Fujiwara R, Urasaki T, Oguchi T, Komai Y, Numao N, Yamamoto S, Yonese J and Yuasa T: Early serum and hematological responses to pembrolizumab therapy as predictors of survival in metastatic urothelial cancer. Anticancer Res 42: 2045 2051, 2022.

22. Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, et al: Prognostic value of the fluctuation in the neutrophil lymphocyte ratio at 6 weeks of pembrolizumab treat ment is specific to the clinical response in metastatic urothelial carcinoma. Urol Oncol 40: 344.e11 344.e17, 2022.

23. Ryman JT and Meibohm B: Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6: 576 588, 2017.

24. Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, et al: Pembrolizumab Exposure response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res 24: 5841 5849, 2018.

25. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E and Robert C: Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24: 1697 1703, 2013.

26. Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, Basu A, Pennell N, Stevenson JP, Elson P, et al: Post treatment changes in hematological parameters predict response to nivolumab mono therapy in non small cell lung cancer patients. PLoS One 13: e0197743, 2018.

27. Karantanos T, Karanika S, Seth B and Gignac G: The absolute lymphocyte count can predict the overall survival of patients with non small cell lung cancer on nivolumab: A clinical study. Clin Transl Oncol 21: 206 212, 2019.

28. Ueda K, Suekane S, Kurose H, Ogasawara N, Hiroshige T, Chikui K, Uemura K, Nakiri M, Nishihara K, Matsuo M, et al: Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab. Jpn J Clin Oncol 52: 179 186, 2022.

29. Lee YJ, Park YS, Lee HW, Park TY, Lee JK and Heo EY: Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non small cell lung cancer. Sci Rep 12: 626, 2022.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る